I am writing to seek your advice on the mapping of TPMT/NUDT15 Genotyping test results.
TPMT/NUDT15 Genotyping is a signtificant biomarker for thropurine toxcity. There are two types of reporting format in our laboratory system based on user perference.
(1) All related information including genes, specimens, methods…etc are treated as a whole and mapped to 93193-1TPMT gene and NUDT15 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method.
(2) Reported in separated sections, e.g. each genotypic findings to specific LOINC concept. But for the clinical interpretation part, should I map to 93193-1TPMT gene and NUDT15 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method like the above case OR I should create an HKLOINC TPMT gene and NUDT15 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method Narrative?
Hello Hiu (and many thanks to Tim for augmenting the original post),
Since report option 2 is using a more granular approach, with LOINC terms for each section, I would suggest saving 93193-1 for reporting option 1 solely.
There are a series of department role review terms, one of which may apply to this Clinical Interpretation. Presuming this is not a pathologist interpretation or a medical director interpretation, which have their own LOINC terms.
You can locate the department role review terms in search.loinc.org by entering review xxx nar
I would suggest using 69047-0 Geneticist review of results
